Tarsus Pharmaceuticals (TARS) Operating Income Growth (1y) (2020 - 2026)
Tarsus Pharmaceuticals (TARS) Operating Income Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 1,386.07% |
| 10 | Tarsus Pharmaceuticals | 2.63 Bn | 2.52 Bn | 152.66 Mn | 76.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.70% |
| Dec 31, 2025 | 67.34% |
| Sep 30, 2025 | 42.26% |
| Jun 30, 2025 | 33.39% |
| Mar 31, 2025 | 30.26% |
| Dec 31, 2024 | 45.06% |
| Sep 30, 2024 | 38.53% |
| Jun 30, 2024 | -1.47% |
| Mar 31, 2024 | -51.03% |
| Dec 31, 2023 | -195.13% |
| Sep 30, 2023 | -78.71% |
| Jun 30, 2023 | -528.27% |
| Mar 31, 2023 | -27.82% |
| Dec 31, 2022 | -4.24% |
| Sep 30, 2022 | -45.85% |
| Jun 30, 2022 | -171.74% |
| Mar 31, 2022 | -282.20% |
| Dec 31, 2021 | -25.89% |
| Sep 30, 2021 | -54.87% |
| Jun 30, 2021 | 323.17% |